东菱迪芙与依达拉奉联合应用对大鼠脑缺血损伤的研究

The effect of Batroxobin combined with Edaravone on the Cerebral Ischemia Injury in Rats

目的探讨东菱迪芙与依达拉奉联合应用对大鼠脑缺血损伤的影响。方法成年健康雄性Wistar大鼠100只,采用改良线栓法制备大鼠大脑中动脉闭塞(MCAO)脑缺血再灌注模型,随机分为5组,即假手术组(正常组)、缺血再灌注组、东菱迪芙治疗组、依达拉奉治疗组、联合用药治疗组。运用组织化学染色技术,检测脑梗死体积;运用循环酶法,检测Hcy水平;运用免疫比浊法,检测hs-CRP浓度变化。结果 1脑缺血再灌注24h后大鼠脑梗死体积显示,东菱迪芙组、依达拉奉组、联合用药组与缺血再灌注组比较,脑梗死体积均缩小,每组间均有显著性差异(P<0.05);联合用药组与东菱迪芙组、依达拉奉组间比较有统计学差异(P<0.05)。2Hcy检测结果显示,缺血再灌注组显著高于正常组(P<0.05);东菱迪芙组显著低于缺血再灌注组(P<0.05);依达拉奉组显著低于缺血再灌注组(P<0.05);东菱迪芙组显著低于依达拉奉组(P<0.05);联合用药组显著低于单药组(P<0.05)。3超敏C-反应蛋白的测定结果显示,缺血再灌注组显著高于正常组(P<0.05);依达拉奉组显著低于缺血再灌注组(P<0.05);东菱迪芙组显著低于缺血再灌注组(P<0.05);东菱迪芙组显著低于依达拉奉组(P<0.05);联合用药组显著低于单药组(P<0.05)。结论 1东菱迪芙与依达拉奉通过缩小急性期脑梗死的梗死体积,降低Hcy和超敏C-反应蛋白水平,可有效减轻脑缺血损伤,均具有脑保护作用。2东菱迪芙与依达拉奉联合应用较单用东菱迪芙治疗或依达拉奉治疗其治疗效果更为显著。

Objective Discssion of Batroxobin and combined use of edaravone on acute cerebral ischemic injury. Methods Modified intraluminal middle cerebral artery occlusion （MCAO）model of cerebral ischemia reperfusion. Healthy adult male Wistar 100 rats,were randomly divided into five groups,sham operation group（normal group）,batr-oxobin in treatment group,Edaravone group,Combined treatment group.Using histochemical staining technique,detec-tion of cerebral infarction volume;by enzymatic cycling assay,detection of Hcy levels;by immune turbidimetry,changes of hs-CRP concentration detection.Results ①Determination of cerebral ischemia and cerebral infarction in rats after 24 h comparison shows the volume：batroxobin group,edaravone group,combination group and ischemia reperfusion model group,both inhibited the volume of cerebral infarction.There was significant difference among groups（P〈0.05）;there were significant difference between combination group and edaravone group,batroxobin group,（P〈0.05）;②Determi-nation of Hcy：The ischemia reperfusion model group was significantly higher than that in normal group（P〈0.05）,ba-troxobin group was significantly lower than that of ischemia reperfusion model group（P〈0.05）,edaravone group was significantly lower than that of the ischemia reperfusion model group（P〈0.05）,batroxobin group was significantly lower than that of edaravone group（P〈0.05）,combination group was significantly lower than that of single drug group （P〈0.05）;③Determination of high sensitivity C-reactive protein：The ischemia reperfusion model group was signifi-cantly higher than that in normal group（P〈0.05）,edaravone group was significantly lower than that of the ischemia reperfusion model group（P〈0.05）,batroxobin group was significantly lower than that of ischemia reperfusion model group（P〈0.05）,batroxobin group was significantly lower than that of edaravone group（P〈0.05）,combination group was significantly lower than single drug group（P〈0.05）.Conclusion Tobishi batroxobin and edaravone can reduce the volume of acute cerebral infarction,and reducing the Hcy and ultra-sensitivity C-reactive protein levels,which can effectively reduce cerebral ischemic inj ury,has protective effect on brain.The treatment of acute cerebral infarction two drugs is only applied in treatment or edaravone Tobishi batroxobin its therapeutic effect is more significant.